Wednesday, February 18, 2026 2/18/2026

Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease

Award Number: R01HL124112
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/22/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease - PROJECT SUMMARY/ABSTRACT For patients with hematologic malignancies such as leukemias, lymphomas and other related cancers, allogeneic hematopoietic cell transplantation (allo HCT) is a critically important therapy that can produce cures when other treatments cannot. Roughly 20,000 patients undergo allo BMT world-wide each year. A major risk of allo HCT continues to be graft-versus-host disease (GVHD), which results from the donor immune system recognizing the transplant recipient’s organs as foreign, leading to life-threatening inflammation. Developing strategies that reduce GVHD but leave global immune function intact should produce a major benefit for patients. One promising approach that we propose testing is targeting the subset of intestinal commensal bacteria that are capable of consuming and degrading mucins, which play a critical role in maintaining the intestinal epithelial barrier and immunological homeostasis. In this proposal, we present preliminary data identifying two common scenarios during the allo HCT process: 1) poor oral dietary intake due to conditioning or development of GVHD, and 2) administration of broad-spectrum antibiotics. Both of these often lead to increases in mucolytic bacteria. Further, we have identified antibiotic and metabolic strategies to suppress mucolytic bacteria activity. We will apply these insights to guide a mucus-focused evaluation of GVHD, in both mouse models and in stool biospecimens collected from allo HCT patients. We and others have identified the microbiota as a potent modulator of acute GVHD severity. This project proposes capitalizing on a mechanistic insight into how this can occur, with clear translational potential.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Blood Diseases and Resources Research	001	11	2/10/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$454,814
2026	2024	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	10	2/9/2026	NON-COMPETING CONTINUATION	-$454,814
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $791,323 )
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	10	7/5/2024	NON-COMPETING CONTINUATION	$791,323
														Subtotal = $791,323

Issue Date FY: 2023 ( Subtotal = $807,472 )
2023	2023	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	9	7/7/2023	NON-COMPETING CONTINUATION	$807,472
														Subtotal = $807,472

Issue Date FY: 2022 ( Subtotal = $807,472 )
2022	2022	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	003	8	7/7/2022	NON-COMPETING CONTINUATION	$807,472
2022	2020	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	002	6	5/25/2022	COMPETING CONTINUATION	$1,173
2022	2019	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	5	11/3/2021	NON-COMPETING CONTINUATION	$0
2022	2019	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	001	5	5/25/2022	NON-COMPETING CONTINUATION	-$1,173
														Subtotal = $807,472

Issue Date FY: 2021 ( Subtotal = $812,650 )
2021	2021	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	001	7	6/30/2021	NON-COMPETING CONTINUATION	$812,650
2021	2019	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	5	4/27/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $812,650

Issue Date FY: 2020 ( Subtotal = $833,292 )
2020	2020	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	6	6/30/2020	COMPETING CONTINUATION	$833,292
														Subtotal = $833,292

Issue Date FY: 2019 ( Subtotal = $512,611 )
2019	2019	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	5	6/6/2019	NON-COMPETING CONTINUATION	$512,611
														Subtotal = $512,611

Issue Date FY: 2018 ( Subtotal = $518,709 )
2018	2018	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Blood Diseases and Resources Research	000	4	6/14/2018	NON-COMPETING CONTINUATION	$518,709
														Subtotal = $518,709

Issue Date FY: 2017 ( Subtotal = $538,525 )
2017	2017	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cardiovascular Diseases Research	004	3	6/20/2017	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$833,643
2017	2017	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cardiovascular Diseases Research	001	3	6/9/2017	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$538,525
2017	2016	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cardiovascular Diseases Research	000	2	6/7/2017	NON-COMPETING CONTINUATION	$0
2017	2016	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cardiovascular Diseases Research	003	2	6/20/2017	NON-COMPETING CONTINUATION	-$587,312
2017	2015	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cardiovascular Diseases Research	002	1	6/20/2017	NEW	-$246,331
														Subtotal = $538,525

Issue Date FY: 2016 ( Subtotal = $587,312 )
2016	2016	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cardiovascular Diseases Research	000	2	5/2/2016	NON-COMPETING CONTINUATION	$587,312
														Subtotal = $587,312

Issue Date FY: 2015 ( Subtotal = $606,287 )
2015	2015	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVENUE	NEW YORK	NY	10065	NEW YORK	USA	Cardiovascular Diseases Research	000	1	8/14/2015	NEW	$606,287
														Subtotal = $606,287

Grand Total All Awards = $6,815,653

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease

Award Number: R01HL124112

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/22/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer